RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.About us
We are interested in cooperation with the authors of new promising ideas in the field of pharmaceuticals and medical equipment.Portfolio
Rusnano and Domain have made an agreement on joint investments in pharmaceuticals and medical development for innovation.About agreement
RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.Our history
RMI venture fund is currently managed by RMI Partners, a venture capital company focused on breakthrough developments of pharmaceutical products and technologies.
RMI was created in March 2012. Initial funding - $380 million. The investor of RMI is RUSNANO, the nanotechnology investment, research and development arm of the Russian Government.
The RusnanoMedInvest fund seeks, in addition to securing differentiated and sustainable returns to its investment portfolio, to promote the following social and developmental objectives in Russia
NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.
28 April 2017
28 April 2017